source
- Ipsen's Dysport shows positive Phase 3 results in migraine, Tarsus acquires iRenix for $75MIpsen reported that its injectable neurotoxin Dysport met the primary endpoint in a Phase 3 trial aimed at reducing monthly migraine days. The trial demonstrated a statistically significant reduct…
- HHS launches Operation Trialblazer to accelerate U.S. drug research amid growing competition from ChinaThe Department of Health and Human Services introduced a new initiative called Operation Trialblazer aimed at speeding early-stage drug research in the United States. The plan calls for coordinate…